children

an Open Access Journal by MDPI

IMPACT FACTOR 2.4

Indexed in: PubMed

CITESCORE 2.0

Advances in Juvenile Idiopathic Arthritis

Guest Editors:

Dr. Giovanni Filocamo
Pediatric Rheumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122 Milan, Italy

Dr. Stefano Lanni
Pediatric Rheumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122 Milan, Italy

Dr. Francesca Minoia
Pediatric Rheumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122 Milan, Italy

Deadline for manuscript submissions:
closed (10 May 2022)

Message from the Guest Editors

Dear colleague,

Juvenile idiopathic arthritis (JIA) is the most common chronic joint disease in pediatric rheumatology and encompasses a heterogeneous group of disorders. JIA is one of the major potential causes of permanent joint inability in childhood, and extra-articular complications such as chronic uveitis could significantly impact its morbidity. Systemic JIA is increasingly recognized as a specific entity with a peculiar crosstalk between the innate and adaptative immune system, and its life-threatening complication, the macrophage activation syndrome, requires prompt recognition and appropriate treatment.

The continuous improvements in translational research, the widespread use of intra-articular glucocorticoids, and the increasing availability of a broad spectrum of innovative therapies that are tailor-made to all different subsets of JIA have resulted in a dramatic change in the way to approach the disease and to a significant improvement of long-term outcomes.

The goal of this Special Issue is to explore all these aspects by pointing out the state-of-the-art knowledge based on daily clinical experience and on evidence from literary reviews.